title: [Assessment of the effects of alfuzosin on miction with dynamic echography].
abstract: Alfuzosina has a specific antagonist effect on the alfa-1-adrenergic post-junctional receptor posed at urethral laeve musculature, prostatic capsule and vesical trgonum. It's and ideal drug the symptoms of the difficult urinary flow typical of the benign prostatic hypertrophia (IPB) and of some patologies of vesical collum to attenuate. With this work we want to demonstrate the anatomic alterations of vesical collum and prostatic urethra by means of dynamic recording mictional phase with transrectal scan carried out before and after treatment. In this study, 30 patients were divided into three groups of 10 in relation to the pathology: overtone of vesical collum, little benign prostatic ipertrophia and great benign prostatic ipertrophia have included. The patients of each group have also been divided in undergroups of five (selected with the method of double-blind) of which the first treated with alfuzosina 7.5 mg/die for 30 days and the second with placebo. Considering the limits of this study, the analysis of the results have permitted to conclude that the drug has determined a subjective improvement in all patients except those with great IPB, while the objective valuation, reached comparing scan dynamic pictures before and after treatment, has made it possible to visualize an improvement on the opening of the vesical collum and the prostatic urethra after therapy with great variations of the size of che mictional funnel and same prostatic urethra. The alfuzosina is efficacious, in the cases under examination, except the third group were the compression on the urethra was of an elevated degree.
authors.affiliation: Divisione di Urologia Clinica San Marco.
authors.forename: M
authors.initials: M
authors.lastname: Milani
authors.forename: A
authors.initials: A
authors.lastname: Mautone
authors.forename: G
authors.initials: G
authors.lastname: Tucci
authors.forename: G
authors.initials: G
authors.lastname: Gentili
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000503:physiopathology; D011799:Quinazolines / Q000627:therapeutic use*; D012720:Severity of Illness Index; D014463:Ultrasonography; D001748:Urinary Bladder Neck Obstruction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D014554:Urination
chemical_list: D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin